Search results
Results from the WOW.Com Content Network
Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), [6] also known as B-lymphocyte stimulator (BLyS). [7] It is approved in the United States [ 8 ] and Canada, [ 9 ] and the European Union [ 5 ] to treat systemic lupus erythematosus and lupus nephritis.
Belimumab (Benlysta) is a monoclonal antibody developed by Human Genome Sciences and GlaxoSmithKline, with significant discovery input by Cambridge Antibody Technology, which specifically recognizes and inhibits the biological activity of B-Lymphocyte stimulator (BLyS) and is in clinical trials for treatment of Systemic lupus erythematosus and ...
The US Food and Drug Administration (FDA) granted the application for belantamab mafodotin priority review, orphan drug, and breakthrough therapy designations. [ 5 ] In 2023, the confirmatory phase III DREAMM-3 trial aimed to compare belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in participants with relapsed or refractory ...
The Food and Drug Administration is expected to render a decision on Arena Pharmaceuticals' (NAS: ARNA) obesity drug lorcaserin by June 27. Except if it doesn't. At the FDA advisory committee ...
Benlysta: mab: human: B-cell activating factor (BAFF) Y: systemic lupus erythematosus without renal or CNS involvement Bemarituzumab [26] mab: humanized: FGFR2: gastric cancer or gastroesophageal junction adenocarcinoma Benralizumab [38] Fasenra: mab: humanized: CD125: Y: asthma Berlimatoxumab [26] mab: human: Staphylococcus aureus bi-component ...
Sales of Human Genome Sciences' (NAS: HGSI) new lupus drug Benylsta continues to grow -- just not fast enough to keep investors interest. The stock traded down more than 20% today after net sales ...
Slow and steady might win the race, but it isn't a way to keep biotech investors' interest. As we approach a year after GlaxoSmithKline (NYS: GSK) and Human Genome Sciences' (NAS: HGSI) Benlysta ...
When the Obama administration announced plans to adjust the cap and increase access to buprenorphine in September, McCoy and his wife wept at the news. The doctor realized his clinic had a chance. He started to accept Medicaid patients because, with more patients coming in, he could afford to take the lower reimbursement rates.